Intravenous and intramuscular.
The lyophilizate must be dissolved in a specially applied solvent immediately before administration. The rest of the drug must be disposed of. The drug should not be mixed with alkaline solutions and solutions containing calcium ions. If the lyophilizate has a color different from white to almost white (due to a crack in the vial or heat exposure), the Geparett® preparation should not be used. The drug Geparett® with intravenous administration is very slow.
Initial therapy:
Intravenous or intramuscular administration: the recommended dose is 5-12 mg / kg / day intravenously or intramuscularly.
Intrahepatic cholestasis
From 400 mg / day to 800 mg / day (1-2 vials a day) for 2 weeks.
Depression
From 400 mg / day to 800 mg / day (1-2 vials a day) for 15-20 days.
If necessary, maintenance therapy is recommended to continue taking ademethionine in the form of tablets at a dose of 800-1600 mg / day for 2-4 weeks.
Therapy with Geparett® can be started with intravenous or intramuscular injection followed by the use of ademethionine in the form of tablets or immediately with the use of the drug in the form of tablets.
Elderly patients
Clinical experience with ademethionine has not revealed any difference in its efficacy in elderly patients and younger patients. However, given the high likelihood of existing violations of the liver, kidney or heart, other concomitant pathologies, or simultaneous therapy with other drugs, the dose of Geparett® should be selected with caution in elderly patients starting with the lower limit of the dose range.
Renal insufficiency
There are limited clinical data on the use of ademetionine in patients with renal insufficiency, and therefore caution should be exercised when using Geparett® in these patients.
Liver failure
The pharmacokinetics of ademetionin are similar in healthy volunteers and in patients with chronic liver disease.
Children
The use of Geparett® in children is contraindicated (efficacy and safety not established).